Secretin

Overview

Secretin holds a unique position in the history of endocrinology as the first substance to be identified as a hormone. In 1902, William Bayliss and Ernest Starling demonstrated that an extract from the duodenal mucosa, when injected intravenously, stimulated pancreatic secretion independently of neural pathways. They named this substance "secretin" and, in doing so, established the concept of hormonal chemical signaling — a discovery that founded the field of endocrinology.

Secretin is a 27-amino acid linear peptide hormone produced by S cells in the crypts of the duodenal and jejunal mucosa. It is released in response to acidic chyme entering the duodenum from the stomach, and its primary physiological role is to stimulate the pancreas to secrete bicarbonate-rich fluid that neutralizes gastric acid in the intestinal lumen. This buffering action is essential for the activity of pancreatic digestive enzymes, which function optimally at neutral to slightly alkaline pH.

Synthetic and recombinant human secretin preparations (marketed as ChiRhoStim and formerly SecreFlo) are FDA-approved diagnostic agents used to assess pancreatic exocrine function and to aid in the localization of gastrinomas in patients with suspected Zollinger-Ellison syndrome.

Structure and Pharmacology

Molecular characteristics:

• Sequence: His-Ser-Asp-Gly-Thr-Phe-Thr-Ser-Glu-Leu-Ser-Arg-Leu-Arg-Asp-Ser-Ala-Arg-Leu-Gln-Arg-Leu-Leu-Gln-Gly-Leu-Val-NH2
• Length: 27 amino acids
• Molecular weight: 3,055.5 Da
• Family: Secretin-Glucagon-VIP superfamily (Class B GPCR ligands)
• Key features: C-terminal amidation required for full biological activity; alpha-helical secondary structure in the C-terminal region

Secretin Receptor Signaling

The secretin receptor (SCTR) is a Class B (secretin-family) G-protein-coupled receptor expressed primarily on:

• Pancreatic ductal epithelial cells (primary target)
• Gastric parietal cells
• Cholangiocytes (bile duct epithelial cells)
• Duodenal Brunner's gland cells
• Select CNS neurons

Signal transduction:

1. Receptor binding: Secretin binds the N-terminal extracellular domain and transmembrane core of SCTR
2. Gs activation: The receptor couples to Gs, activating adenylyl cyclase
3. cAMP generation: Elevated intracellular cAMP activates protein kinase A (PKA)
4. CFTR activation: In pancreatic ductal cells, PKA phosphorylates CFTR chloride channels and chloride-bicarbonate exchangers
5. Bicarbonate secretion: Chloride efflux through CFTR drives bicarbonate secretion into the ductal lumen via apical Cl-/HCO3- exchangers, with water following osmotically
6. Volume output: The net effect is secretion of large volumes of alkaline, bicarbonate-rich pancreatic juice

Physiological Functions

Pancreatic effects:

• Stimulates bicarbonate and water secretion from pancreatic ductal cells (primary action)
• Potentiates Cholecystokinin-stimulated enzyme secretion from acinar cells
• Regulates pancreatic growth and maintenance

Gastric effects:

• Inhibits gastric acid secretion (provides negative feedback on acid delivery to the duodenum)
• Inhibits gastric motility and gastric emptying

Hepatobiliary effects:

• Stimulates bile flow (choleresis) from cholangiocytes
• Increases hepatic bicarbonate secretion into bile

Other effects:

• Stimulates Brunner's gland mucus secretion in the duodenum
• Regulates water homeostasis through interactions with hypothalamic centers
• Modulates food intake via vagal afferent signaling

Clinical Applications

Pancreatic Function Testing

The secretin stimulation test is used to assess pancreatic exocrine reserve:

• Procedure: Synthetic human secretin (0.2 mcg/kg) is administered intravenously, and duodenal aspirates are collected at timed intervals to measure bicarbonate concentration, fluid volume, and enzyme output
• Indication: Diagnosis of chronic pancreatitis and evaluation of pancreatic exocrine insufficiency
• Interpretation: Reduced bicarbonate concentration (< 80 mEq/L) and fluid volume suggest impaired ductal function

Gastrinoma Localization

The secretin stimulation test is a key diagnostic tool for Zollinger-Ellison syndrome (ZES):

• Principle: In patients with gastrinomas, intravenous secretin paradoxically stimulates a marked rise in serum gastrin levels, whereas in normal individuals, secretin suppresses Gastrin release
• Procedure: Serum gastrin is measured at baseline and at 2, 5, 10, 15, and 30 minutes after IV secretin (0.4 mcg/kg)
• Positive result: An increase in serum gastrin of >120 pg/mL above baseline is consistent with gastrinoma
• Mechanism: Gastrinoma cells express secretin receptors that paradoxically stimulate gastrin release, unlike normal antral G cells

Additional Diagnostic Uses

• Magnetic resonance cholangiopancreatography (MRCP): Secretin-enhanced MRCP provides dynamic imaging of pancreatic duct anatomy and flow
• Assessment of sphincter of Oddi function: Evaluation of biliary and pancreatic sphincter dynamics

Pharmacokinetics

The very short half-life reflects rapid proteolytic degradation, consistent with the transient, meal-responsive nature of physiological secretin signaling.

Safety Profile

Secretin has an excellent safety profile when used diagnostically:

• Mild adverse effects: Flushing, abdominal discomfort, mild nausea (infrequent)
• Allergic reactions: Rare; more common historically with porcine-derived preparations than with synthetic human secretin
• Hemodynamic effects: Transient, mild hypotension may occur due to vasodilatory properties

Serious adverse events are exceedingly rare at diagnostic doses.

Dosing Protocols

The following dosing information reflects FDA-approved clinical guidelines. Synthetic human secretin (ChiRhoStim) is an FDA-approved diagnostic agent. Always consult a qualified healthcare professional.

Administration notes: This is a diagnostic agent only. Administered by healthcare professionals in clinical or imaging settings. Patient should fast before testing. An increase in serum gastrin of more than 120 pg/mL above baseline is consistent with gastrinoma.

Historical and Scientific Significance

Secretin's identification by Bayliss and Starling in 1902 was transformative for biology. Prior to their work, physiological regulation was understood primarily through nervous system control (the prevailing Pavlovian model). Their demonstration that a chemical substance produced in one organ (duodenum) could travel through the blood to regulate another organ (pancreas) established the endocrine principle. Starling subsequently coined the term "hormone" (from the Greek hormon, meaning "to arouse") to describe such chemical messengers.

Secretin also played a historical role in the development of understanding the secretin-glucagon-VIP peptide superfamily, a group of structurally related peptide hormones that bind Class B GPCRs and regulate diverse gastrointestinal, metabolic, and neurological functions. This family includes Glucagon, VIP, glucose-dependent insulinotropic peptide (GIP), and the GLP-1 agonists such as Semaglutide.